Program
SAR402663
A development code.
In Sanofi's pipeline, sFLT01 AAV gene therapy
. Its studies are mostly in Macular Degeneration, led by Sanofi.
Furthest: phase 2, since Oct 25, 20241 company-led study, 1 open or runningNext primary completion: May 18, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanofi | 11 open or running | phase 2since Oct 25, 2024 | Oct 25, 2024 | May 18, 2027phase 2 · NCT06660667 |
- Named in Sanofi’s own pipeline as
SAR402663
, phase 2, as of Sep 30, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 25, 2024First study: phase 2 study in Neovascular Age-related Macular DegenerationFirst studyNCT06660667 · 66 enrolled · United States, United Kingdom
Ahead
- May 18, 2027Primary completion: phase 2 study in Neovascular Age-related Macular DegenerationNCT06660667
TargetBeta
“sFLT01 AAV gene therapy”the company's pipeline, read by Claude · source
Other programs on FLT1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| lenvatinibrule | Eisai | phase 4 | 81 |
| nintedanibrule | Boehringer Ingelheim | phase 4 | 76 |
| regorafenibrule | Bayer | phase 4 | 40 |
| Axitinibrule | Pfizer | phase 3 | 45 |
| chiauranibrule | Chipscreen Biosciences | phase 3 | 15 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06660667Neovascular Age-related Macular Degeneration · United States, United Kingdom | 2 | Active, not recruiting | May 18, 2027 | 66 |
How it is read
Names in the registry
- “SAR402663”, 1 entry
Codes read as this program: SAR402663.
Conditions, from the studies’ own filings
- Macular Degeneration, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.